RUNX2 and prostate cancer: Low expression of Runx2 was associated with aggressive clinicopathological characteristics for patients with prostate cancer, but most patients with metastatic disease were Runx2 nuclear staining positive, which suggested that the nuclear location of Runx2 was related with metastasis in prostate cancer10.